A reexamination of the stable category for evaluating response in patients with advanced prostate cancer (Q70361315)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6375857%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

title

A reexamination of the stable category for evaluating response in patients with advanced prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6375857%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

1 reference

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

11 October 2023

author name string

N. H. Slack

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6375857

11 October 2023

M. F. Brady

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6375857

11 October 2023

G. P. Murphy

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6375857

11 October 2023

language of work or name

English

0 references

publication date

1 August 1984

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6375857%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

10 October 2019

number of pages

11

1 reference

based on heuristic

inferred from page(s)

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

11 October 2023

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

11 October 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6375857%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6375857%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6375857%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

page(s)

564-574

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6375857%20AND%20SRC:MED&resulttype=core&format=json

Cancer chemotherapy reports

10 October 2019

cites work

2

59

195

Scott

1975

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Cancer chemotherapy reports

11 October 2023

3

52

641

Moore

1968

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Chemotherapy of advanced prostatic cancer. Evaluation of response parameters

11 October 2023

4

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

11 October 2023

5

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

CLINICAL CANCER OF THE PROSTATE: A STUDY OF 4,000 CASES

11 October 2023

6

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases

11 October 2023

7

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Proceedings: Etiology, epidemiology, and pathology of prostatic cancer.

11 October 2023

9

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Proceedings: The natural history of prostatic cancer

11 October 2023

10

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer

11 October 2023

11

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Chemotherapy Programs of the National Prostatic Cancer Project (NPCP)

11 October 2023

12

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Overview of chemotherapy programs of the NPCP

11 October 2023

13

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Comparison of Estramustine Phosphate and Vincristine Alone or in Combination for Patients with Advanced, Hormone Refractory, Previously Irradiated Carcinoma of the Prostate

11 October 2023

14

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate

11 October 2023

15

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

11 October 2023

16

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate

11 October 2023

17

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

11 October 2023

18

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area

11 October 2023

19

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Value of new fluorescent immunoassay for human prostatic acid phosphatase in prostate cancer

11 October 2023

21

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

The use of serum isoenzymes of alkaline and acid phosphatase as possible quantitative markers of tumor load in prostate cancer

11 October 2023

23

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Response criteria for the prostate of the USA national prostatic cancer project

11 October 2023

25

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Maximum utilization of the life table method in analyzing survival

11 October 2023

26

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

11 October 2023

Federation Proceedings

28

13

815

Bross

1954

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

11 October 2023

29

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

11 October 2023

31

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

Systemic treatment of advanced prostatic cancer: development of a new system for defining response.

11 October 2023

32

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer

11 October 2023

33

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

11 October 2023

Cancer Treatment Reports

35

60

115

Eagan

1976

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

11 October 2023

Cancer Treatment Reports

36

61

325

DeWys

1977

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

The influence of site of metastasis on tumour growth and response to chemotherapy

11 October 2023

37

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

The value of nuclear bone imaging in advanced prostatic cancer

11 October 2023

38

1 reference

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

https://api.crossref.org/works/10.1002/1097-0142(19840801)54:3%3C564::AID-CNCR2820540330%3E3.0.CO;2-6

11 October 2023

Identifiers

10.1002/1097-0142(19840801)54:3<564::AID-CNCR2820540330>3.0.CO;2-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6375857%20AND%20SRC:MED&resulttype=core&format=json

10 October 2019

1 reference